SWOG clinical trial number
CTSU/A031901
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Open
Phase
Abbreviated Title
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Status Notes
SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Activated
05/01/2021
Participants
CTSU
Research committees
Genitourinary Cancer
Treatment
Nivolumab
Atezolizumab
durvalumab
Avelumab
Pembrolizumab
Eligibility Criteria Expand/Collapse
Please contact CTSU directly by phone (888/823-5923) or on the CTSU website (https://www.ctsu.org) for more information and registration procedures.
Other Clinical Trials
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2011
Randomized Phase II Trial Of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery For Cisplatin-Ineligible Muscle-Ineligible Urothelial Carcinoma: SWOG GAP TRIAL
Research Committee(s)
Genitourinary Cancer
Activated
10/06/2021
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA8185
Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase